Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acyclovir prophylaxis for herpes simplex virus infection.

D Gold, L Corey

    Antimicrobial Agents and Chemotherapy
    |March 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Extended C-band tunable multi-channel InP-based coherent receiver PICs.

    Optics express·2017
    Same author

    Human papillomavirus tumour status is not associated with a positive depression screen for patients with oropharyngeal cancer.

    The Journal of laryngology and otology·2017
    Same author

    Recurrent "pericardial pain" after pericardiectomy for recurrent acute benign pericarditis.

    Circulation·2015
    Same author

    DG-RAR for the treatment of symptomatic grade III and grade IV haemorrhoids: a 12-month multi-centre, prospective observational study.

    European surgery : ACA : Acta chirurgica Austriaca·2013
    Same author

    Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.

    Cell death and differentiation·2007
    Same author

    Late-onset fistula presenting as buttock abscess in two patients with ileo-anal J-pouches for ulcerative colitis.

    Techniques in coloproctology·2004
    Same journal

    <i>In vitro</i> antibacterial activity of gepotidacin in combination with other antimicrobial agents against <i>Neisseria gonorrhoeae</i> isolates.

    Antimicrobial agents and chemotherapy·2026
    Same journal

    Development of domain-specific probes of <i>Plasmodium falciparum</i> heat shock protein 70-1.

    Antimicrobial agents and chemotherapy·2026
    Same journal

    Addressing therapeutic options for KPC-3-producing ST307-<i>Klebsiella pneumoniae</i>: insights from <i>in vitro</i> evolution and mutant prevention strategies.

    Antimicrobial agents and chemotherapy·2026
    Same journal

    Indole-based hybrids target both asexual parasites and gametocytes of <i>Plasmodium falciparum</i> and synergize with lumefantrine.

    Antimicrobial agents and chemotherapy·2026
    Same journal

    Lineage-specific loss of the type VI secretion system in <i>Acinetobacter baumannii</i> ST19 is associated with reduced accessory genome content.

    Antimicrobial agents and chemotherapy·2026
    Same journal

    Genomic diversity and topical antimicrobial resistance in <i>Staphylococcus aureus</i> from clinical and carriage populations in the New York-New Jersey region.

    Antimicrobial agents and chemotherapy·2026
    See all related articles

    Acyclovir (ACV) effectively treats and prevents herpes simplex virus (HSV) infections in immunocompromised and normal individuals. This well-tolerated antiviral is recommended for organ transplant recipients and chemotherapy patients, and for those with recurrent genital herpes.

    Area of Science:

    • Virology
    • Immunology
    • Pharmacology

    Background:

    • Herpes simplex virus (HSV) infections pose significant risks, particularly in immunocompromised individuals.
    • Effective antiviral prophylaxis and treatment are crucial for managing HSV in vulnerable populations.
    • Acyclovir (ACV) is a widely used antiviral agent for HSV.

    Purpose of the Study:

    • To evaluate the efficacy and safety of Acyclovir (ACV) for HSV treatment and prophylaxis.
    • To determine the role of ACV in managing HSV in immunocompromised and immunocompetent individuals.
    • To establish guidelines for ACV use in specific patient groups, including transplant recipients and chemotherapy patients.

    Main Methods:

    • Review of clinical data on Acyclovir (ACV) efficacy and tolerability.

    Related Experiment Videos

  • Analysis of Acyclovir's (ACV) impact on HSV infections in different immunological states.
  • Assessment of Acyclovir's (ACV) safety profile, including clinical and laboratory toxicities.

    • Main Results:

    • Acyclovir (ACV) demonstrated effectiveness in both treating and preventing HSV infections.
    • The drug was well-tolerated across all patient populations studied.
    • No significant clinical or laboratory toxicities were associated with Acyclovir (ACV) use.

    Conclusions:

    • Acyclovir (ACV) is a safe and effective agent for HSV management in immunocompromised and normal individuals.
    • Routine HSV antibody screening and prophylactic ACV are recommended for organ transplant recipients and chemotherapy patients.
    • Long-term ACV suppression is a viable option for immunocompetent individuals with recurrent or complicated genital HSV.